Empowered Patient Podcast

Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or a fatal overdose. SOOPR is a rescue agent designed specifically for overdoses from synthetic opioids, particularly fentanyl, which can last longer and be more potent than traditional opioids.

Greg explains, "Anytime there's an epidemic, you want to control exposure. The tricky bit in the area of pain management and the use of opioids is how do you control exposure without affecting patient care. We've come up with a technology that maintains the unmatched efficacy of the opioids. But when somebody takes too many pills, and we've actually shown this in our human study, we can reduce the exposure because we use this proprietary molecular delivery system that uses the body's natural digestive process to control how much of the opioid gets released. That's how we're addressing the front end of the issue, where somebody is prescribed an opioid."

"But sadly, what happens today is several individuals progress along the road to opioid use disorder, and they end up using illicit drugs. That's where our second program, SOOPR, comes into play. As you know, our streets in the US have been flooded with fentanyl. Fentanyl is a highly potent opioid. The cartels have gotten very wise in how to expand their market. They introduced fentanyl-laced pills because a lot more people are willing to take pills rather than inject. Well, that changed the game dramatically because when somebody overdoses orally on fentanyl, that puts them at risk of respiratory depression for hours where they stop breathing."

"Existing rescue agents like Narcan and Opvee weren't designed for oral synthetic opioids and overdoses of those drugs. ‎SOOPR, we believe, is the first rescue agent designed specifically for synthetic opioids. What it does is it outlasts that synthetic opioid danger zone, blocking the mu-opioid receptors and preventing that respiratory depression or rescuing somebody who's already in respiratory depression."

#ElysiumTherapeutics #Opioids #OpioidAbuse #SyntheticOpioids #OpioidUseDisorder #PainManagement #SaferMedicines

Elysiumrx.com

Listen to the podcast here

Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or a fatal overdose. SOOPR is a rescue agent designed specifically for overdoses from synthetic opioids, particularly fentanyl, which can last longer and be more potent than traditional opioids.

Greg explains, "Anytime there's an epidemic, you want to control exposure. The tricky bit in the area of pain management and the use of opioids is how do you control exposure without affecting patient care. We've come up with a technology that maintains the unmatched efficacy of the opioids. But when somebody takes too many pills, and we've actually shown this in our human study, we can reduce the exposure because we use this proprietary molecular delivery system that uses the body's natural digestive process to control how much of the opioid gets released. That's how we're addressing the front end of the issue, where somebody is prescribed an opioid."

"But sadly, what happens today is several individuals progress along the road to opioid use disorder, and they end up using illicit drugs. That's where our second program, SOOPR, comes into play. As you know, our streets in the US have been flooded with fentanyl. Fentanyl is a highly potent opioid. The cartels have gotten very wise in how to expand their market. They introduced fentanyl-laced pills because a lot more people are willing to take pills rather than inject. Well, that changed the game dramatically because when somebody overdoses orally on fentanyl, that puts them at risk of respiratory depression for hours where they stop breathing."

"Existing rescue agents like Narcan and Opvee weren't designed for oral synthetic opioids and overdoses of those drugs. ‎SOOPR, we believe, is the first rescue agent designed specifically for synthetic opioids. What it does is it outlasts that synthetic opioid danger zone, blocking the mu-opioid receptors and preventing that respiratory depression or rescuing somebody who's already in respiratory depression."

#ElysiumTherapeutics #Opioids #OpioidAbuse #SyntheticOpioids #OpioidUseDisorder #PainManagement #SaferMedicines

Elysiumrx.com

Download the transcript here

Dr. Boris Reznik, Chairman and CEO of Immorta Bio, was founded to explore longevity and life extension technologies inspired by the discovery that aged cells can be reprogrammed to become younger ones. The company has a cellular rejuvenation platform that uses the patient's cells and senolytic immunotherapy to help the immune system target and remove senescent cells. These approaches aim to leverage the body's natural mechanism for maintaining health and extending the healthspan, not just lifespan.

Boris explains, "First of all, let me just touch upon aging because aging perpetually happens on a cellular level from an early age because trillions of mutations occur in our cells every single day. But the young body's defense mechanism, such as the immune system and stem cells, effectively addresses those issues and keeps young people healthy. So everything we do is associated with the approach where we try to use young bodies' mechanisms in dealing with all diseases and all issues associated with aging."

"As I said, young bodies have mechanisms, but all mechanisms which body uses, they have a tendency to deteriorate with age, and it starts all on cellular level. They progress from cells to tissues, from tissues to organs, from organs to systems, and, eventually, all of that results in a disease. And those diseases are what we call diseases of aging. So, actually, the disease of aging is just a specific stage of aging. So, what we created and what we focus on are the two fundamental areas of longevity technologies."

#ImmortaBio #Longevity #StemCells #Cancer #Aging #Rejuvenation

immortabio.com

Listen to the podcast here

Dr. Boris Reznik, Chairman and CEO of Immorta Bio, was founded to explore longevity and life extension technologies inspired by the discovery that aged cells can be reprogrammed to become younger ones. The company has a cellular rejuvenation platform that uses the patient's cells and senolytic immunotherapy to help the immune system target and remove senescent cells. These approaches aim to leverage the body's natural mechanism for maintaining health and extending the healthspan, not just lifespan.

Boris explains, "First of all, let me just touch upon aging because aging perpetually happens on a cellular level from an early age because trillions of mutations occur in our cells every single day. But the young body's defense mechanism, such as the immune system and stem cells, effectively addresses those issues and keeps young people healthy. So everything we do is associated with the approach where we try to use young bodies' mechanisms in dealing with all diseases and all issues associated with aging."

"As I said, young bodies have mechanisms, but all mechanisms which body uses, they have a tendency to deteriorate with age, and it starts all on cellular level. They progress from cells to tissues, from tissues to organs, from organs to systems, and, eventually, all of that results in a disease. And those diseases are what we call diseases of aging. So, actually, the disease of aging is just a specific stage of aging. So, what we created and what we focus on are the two fundamental areas of longevity technologies."

#ImmortaBio #Longevity #StemCells #Cancer #Aging #Rejuvenation

immortabio.com

Download the transcript here

Randy Boldyga is the CEO, President, and Founder of RXNT, which provides electronic medical records, electronic prescribing, and practice management products. One primary focus is improving patient charts using AI tools to enable providers to communicate with patients more efficiently and effectively. Using predictive analytics and virtual health assistants, this approach can improve patient outcomes by making healthcare more personalized and proactive.

Randy explains, "There are things like enhanced diagnostics, in which AI can analyze medical images such as X-rays and MRIs with high accuracy, and personalized medicine, where AI can process and interpret genetic information, helping to tailor treatments to individual patients. There are predictive analytics, operational efficiencies such as AI, and streamlining administrative tasks for their office, such as scheduling, billing, and managing patient records."

"There's virtual health assistance where AI-powered chatbots and individual assistance can help with appointment scheduling and offer medication reminders, improving patient engagement and adherence. There's robotic surgery, drug discovery and development, remote monitoring, enhanced patient records, and training and education. So those are all areas where AI has the potential to make healthcare more personalized, efficient, and proactive, leading to better patient outcomes in a more streamlined system."

#RXNT #PatientCharts #MedAI #PersonalizedMedicine #AI #MedTech

RXNT.com

Listen to the podcast here

Randy Boldyga is the CEO, President, and Founder of RXNT, which provides electronic medical records, electronic prescribing, and practice management products. One primary focus is improving patient charts using AI tools to enable providers to communicate with patients more efficiently and effectively. Using predictive analytics and virtual health assistants, this approach can improve patient outcomes by making healthcare more personalized and proactive.

Randy explains, "There are things like enhanced diagnostics, in which AI can analyze medical images such as X-rays and MRIs with high accuracy, and personalized medicine, where AI can process and interpret genetic information, helping to tailor treatments to individual patients. There are predictive analytics, operational efficiencies such as AI, and streamlining administrative tasks for their office, such as scheduling, billing, and managing patient records."

"There's virtual health assistance where AI-powered chatbots and individual assistance can help with appointment scheduling and offer medication reminders, improving patient engagement and adherence. There's robotic surgery, drug discovery and development, remote monitoring, enhanced patient records, and training and education. So those are all areas where AI has the potential to make healthcare more personalized, efficient, and proactive, leading to better patient outcomes in a more streamlined system."

#RXNT #PatientCharts #MedAI #PersonalizedMedicine #AI #MedTech

RXNT.com

Download the transcript here

Joseph Mossel, CEO and Co-Founder of Ibex Medical Analytics is developing AI-based cancer diagnostic technology to help pathologists work faster and more accurately with tissue samples. This technology is being widely adopted as an artificial pathologist that can perform tasks more efficiently and aid the pathologist in reducing error rates, which is ever more important with the shortage of pathologists and increasing demand. Partnering with pharma companies, this technology has the potential to develop algorithms that can help determine the effectiveness of specific cancer drugs, expanding the application of AI beyond improving diagnostic accuracy.

Joseph explains, "Pathology labs know how to receive a biopsy and a tissue sample and then convert it into a slide. Then, it is diagnosed by the pathologist. Our technology, not only does it help the pathologist to do their work faster, but it also is embedded within the lab workflow. You can think of the lab as the kind of a factory here, and we help all of that to be more efficient and faster. In some cases, we can actually cut down the time to diagnosis by even a few days."

"Many studies that we've run with pathologists found that using our AI is better than just the AI and better than pathologists not using the AI. And you'll ask soon better by how much. That depends on the specific pathologists and the lab. But we've seen good labs with an error rate of around 2% to 3%. And by error, I mean really missing a cancer diagnosis, so diagnosing a cancerous case as benign. And then the absolute worst we've ever seen was a lab where 20% of the cases were misdiagnosed, which was a bit shocking. With a pathologist using our algorithm, the advantage of the two working together is that the algorithm and the pathologist tend to make different mistakes. Working together, we get to a level where there's maybe a handful of mistakes in every 10,000 cases."

#IbexMedicalAnalytics #CancerDiagnostics #Cancer #DigitalPathology #Pathology #AI #AIinPathology #PatientOutcomes

ibex-ai.com

Listen to the podcast here

Joseph Mossel, CEO and Co-Founder of Ibex Medical Analytics is developing AI-based cancer diagnostic technology to help pathologists work faster and more accurately with tissue samples. This technology is being widely adopted as an artificial pathologist that can perform tasks more efficiently and aid the pathologist in reducing error rates, which is ever more important with the shortage of pathologists and increasing demand. Partnering with pharma companies, this technology has the potential to develop algorithms that can help determine the effectiveness of specific cancer drugs, expanding the application of AI beyond improving diagnostic accuracy.

Joseph explains, "Pathology labs know how to receive a biopsy and a tissue sample and then convert it into a slide. Then, it is diagnosed by the pathologist. Our technology, not only does it help the pathologist to do their work faster, but it also is embedded within the lab workflow. You can think of the lab as the kind of a factory here, and we help all of that to be more efficient and faster. In some cases, we can actually cut down the time to diagnosis by even a few days."

"Many studies that we've run with pathologists found that using our AI is better than just the AI and better than pathologists not using the AI. And you'll ask soon better by how much. That depends on the specific pathologists and the lab. But we've seen good labs with an error rate of around 2% to 3%. And by error, I mean really missing a cancer diagnosis, so diagnosing a cancerous case as benign. And then the absolute worst we've ever seen was a lab where 20% of the cases were misdiagnosed, which was a bit shocking. With a pathologist using our algorithm, the advantage of the two working together is that the algorithm and the pathologist tend to make different mistakes. Working together, we get to a level where there's maybe a handful of mistakes in every 10,000 cases."

#IbexMedicalAnalytics #CancerDiagnostics #Cancer #DigitalPathology #Pathology #AI #AIinPathology #PatientOutcomes

ibex-ai.com

Download the transcript here

Dr. Chris Heery is Chief Medical Officer at Arcellx, a company focusing on developing anito-cel, a significant advancement in CAR-T cell therapy, to treat relapsed and refractory multiple myeloma (rrMM). Multiple myeloma is a rare type of blood cancer that affects plasma cells in the bone marrow and has few treatment options. Arcellx is showing promising data from clinical trials with patients with rrMM who have failed prior therapies and have received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA for anito-cel.

Chris explains, "The company was founded based on an idea that you could take a novel protein structure and modify it to be able to bind to targets on the surface of cancer cells. And over many years of work, the founders were able to demonstrate that that was possible. Over the last three or four years, Arcellx has focused more on taking what were some of those early ideas and turning them into a product that can help patients. For these last three or four years, most of our focus has been around the lead asset that we call anito-cel that treats multiple myeloma and trying to get that product through the approval process to be able to be a commercial product that can be used for patients both in the United States and the rest of the world."

"When a patient is diagnosed with multiple myeloma, in general, most patients are older. The median age of diagnosis of multiple myeloma is around 70 years old, and those plasma cells can cause damage to the normal bone marrow by crowding out the normal bone marrow."

"They can also make a lot of the protein that a normal plasma cell would make. By making a lot of that protein, those proteins can cause deposition and damage into other tissues. So, patients can arrive at the clinic with a variety of different symptoms that have to do with either decreased bone marrow activity, decreased number of normal cell populations in their blood, or damage to things like their kidneys or other end organs that you need for normal human function."

#Arcellx #CellTherapy #CARTTherapy #RRMM #MultipleMyeloma #BloodCancer #Cancer #RareDisease

arcellx.com

Listen to the podcast here

Dr. Chris Heery is Chief Medical Officer at Arcellx, a company focusing on developing anito-cel, a significant advancement in CAR-T cell therapy, to treat relapsed and refractory multiple myeloma (rrMM). Multiple myeloma is a rare type of blood cancer that affects plasma cells in the bone marrow and has few treatment options. Arcellx is showing promising data from clinical trials with patients with rrMM who have failed prior therapies and have received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA for anito-cel.

Chris explains, "The company was founded based on an idea that you could take a novel protein structure and modify it to be able to bind to targets on the surface of cancer cells. And over many years of work, the founders were able to demonstrate that that was possible. Over the last three or four years, Arcellx has focused more on taking what were some of those early ideas and turning them into a product that can help patients. For these last three or four years, most of our focus has been around the lead asset that we call anito-cel that treats multiple myeloma and trying to get that product through the approval process to be able to be a commercial product that can be used for patients both in the United States and the rest of the world."

"When a patient is diagnosed with multiple myeloma, in general, most patients are older. The median age of diagnosis of multiple myeloma is around 70 years old, and those plasma cells can cause damage to the normal bone marrow by crowding out the normal bone marrow."

"They can also make a lot of the protein that a normal plasma cell would make. By making a lot of that protein, those proteins can cause deposition and damage into other tissues. So, patients can arrive at the clinic with a variety of different symptoms that have to do with either decreased bone marrow activity, decreased number of normal cell populations in their blood, or damage to things like their kidneys or other end organs that you need for normal human function."

#Arcellx #CellTherapy #CARTTherapy #RRMM #MultipleMyeloma #BloodCancer #Cancer #RareDisease

arcellx.com

Download the transcript here